Linike Medical Group Ltd.

As of July 31, 2014, Linike Medical Group Ltd. carries a market capitalization of 3.04B, placing it among publicly traded companies globally. Its enterprise value stands at 3.04B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of July 31, 2014, Linike Medical Group Ltd. has 3.47M shares outstanding.

These figures are as of July 31, 2014.

These figures cover the twelve months ended July 31, 2014. Return on assets (ROA) is negative at -278.62, reflecting losses generated across the asset base.

As of the close on October 22, 2026, Linike Medical Group Ltd.'s stock has declined approximately 62.00% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.24.

Over the twelve months ended July 31, 2014, Linike Medical Group Ltd. generated - - in revenue and converted that into -306,894.00 in net income, yielding earnings per share of -0.09. EBITDA reached -303,869.00, while operating income came in at -93,673.00.

These figures are as of July 31, 2014. Total book value stands at -532,919.00, with working capital of -531,589.00 providing operational flexibility.

Linike Medical Group Ltd. produced 100,472.00 in operating cash flow over the twelve months ended July 31, 2014.

These figures cover the twelve months ended July 31, 2014. Free cash flow yield stands at 0.00, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 0.01, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Linike Medical Group Ltd. shareholders.

Linike Medical Group Ltd.'s most recent stock split took place on June 8, 2020 with a 50:1 split ratio.

As of July 31, 2014, Linike Medical Group Ltd. has an Altman Z-Score of -8,340.62, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.